Use of Radio-Labeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning, New England Journal of Medicine, vol.298, issue.25, pp.1384-1386, 1978. ,
DOI : 10.1056/NEJM197806222982503
Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.3, issue.5517, pp.495-497, 1975. ,
DOI : 10.1042/bj1280427
Study of antibodies against human melanoma produced by somatic cell hybrids., Proc. Natl. Acad. Sci, pp.3405-3409, 1978. ,
DOI : 10.1073/pnas.75.7.3405
Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies., Proc. Natl. Acad. Sci. USA 1979, pp.1438-1442 ,
DOI : 10.1073/pnas.76.3.1438
Differences in Experimental Tumor Localization of Dual-Labeled Monoclonal Antibody, J. Nucl. Med, vol.27, pp.1293-1299, 1986. ,
Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA X Anti-DTPA-Indium Bispecific Antibody, J. Nucl. Med, vol.39, pp.1172-1178, 1998. ,
Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges, Expert Opinion on Biological Therapy, vol.5, issue.sup1, pp.15-27, 2005. ,
DOI : 10.1073/pnas.96.5.1898
Immunotherapy of Non-Hodgkin's Lymphomas. Hematol, Am. Soc. Hematol. Educ. Program, pp.221-240, 2001. ,
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-792, 2001. ,
DOI : 10.1056/NEJM200103153441101
Radioimmunotherapy with Iodine (131)I Tositumomab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results and Long-Term Follow-up of the University of Michigan Experience, Blood, vol.96, pp.1259-1266, 2000. ,
A Phase I/II Trial of Iodine-131-Tositumomab (anti-CD20, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation for Relapsed B-Cell Lymphomas, pp.2934-2942, 2000. ,
,
Radioimmunoconjugates for the Treatment of Cancer, Semin. Oncol, vol.41, pp.613-622, 2014. ,
Immuno-PET of Cancer: A Revival of Antibody Imaging, Journal of Nuclear Medicine, vol.52, issue.8, pp.1171-1172, 2011. ,
DOI : 10.2967/jnumed.111.089771
PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET, Tumor Biology, vol.353, issue.Suppl 1, pp.607-615, 2012. ,
DOI : 10.1056/NEJMoa050753
Radiolabeled Antibodies for Cancer Imaging and Therapy, Methods Mol. Biol, vol.907, pp.681-697, 2012. ,
DOI : 10.1007/978-1-61779-974-7_38
Clinical radioimmunotherapy???the role of radiobiology, Nature Reviews Clinical Oncology, vol.33, issue.12, pp.720-734, 2011. ,
DOI : 10.1158/1078-0432.CCR-1004-0023
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated, International Journal of Radiation Oncology*Biology*Physics, vol.58, issue.3, pp.862-870, 2004. ,
DOI : 10.1016/j.ijrobp.2003.09.012
Kraeber-Bodéré, F. Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma. Front, Oncol, vol.2013, issue.3, p.177 ,
I-Labetuzumab After Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy Results, Journal of Clinical Oncology, vol.23, issue.27, pp.6763-6770, 2005. ,
DOI : 10.1200/JCO.2005.18.622
Anti-prostate-Specific membrane antigen-based radioimmunotherapy for prostate cancer, Cancer, vol.23, issue.suppl 10 pt 2, pp.1075-1083, 2010. ,
DOI : 10.1016/1078-1439(95)00004-2
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy, Journal of Clinical Oncology, vol.24, issue.5, pp.823-834, 2006. ,
DOI : 10.1200/JCO.2005.03.8471
,
Survival Improvement in Patients with Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti-Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study with the French Endocrine Tumor Group ,
, J. Clin. Oncol, vol.24, pp.1705-1711, 2006.
Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131 I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial, J. Nucl. Med, vol.47, pp.247-255, 2006. ,
Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement, Journal of Nuclear Medicine, vol.53, issue.8, pp.1185-1192, 2012. ,
DOI : 10.2967/jnumed.111.101865
URL : https://hal.archives-ouvertes.fr/hal-00932253
Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results, British Journal of Cancer, vol.20, issue.4, pp.934-942, 2013. ,
DOI : 10.1200/JCO.2002.11.076
Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer, Cancer, vol.6, issue.suppl, pp.5497-5506, 2012. ,
DOI : 10.1016/S1040-8428(00)00136-0
Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors, Journal of Cancer Research and Therapeutics, vol.5, issue.9, pp.36-40, 2009. ,
DOI : 10.4103/0973-1482.55139
Relationships between Tumor Size and Curability for Uniformly Targeted Therapy with Beta-Emitting Radionuclides, J. Nucl. Med, vol.36, pp.1902-1909, 1995. ,
Phase III Trial of Consolidation Therapy With Yttrium-90???Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma, Journal of Clinical Oncology, vol.26, issue.32, pp.5156-5164, 2008. ,
DOI : 10.1200/JCO.2008.17.2015
90 Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results after a Median Follow-up of 7.3 Years from the International, Randomized, Phase III First-LineIndolent Trial, J. Clin. Oncol, pp.31-1977, 2013. ,
Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing 125I-Labeled Monoclonal Antibodies, Journal of Nuclear Medicine, vol.51, issue.11, pp.1748-1755, 2010. ,
DOI : 10.2967/jnumed.110.080226
URL : https://hal.archives-ouvertes.fr/inserm-00531603
Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis, Journal of Nuclear Medicine, vol.50, issue.12, pp.2033-2041, 2009. ,
DOI : 10.2967/jnumed.109.066993
URL : https://hal.archives-ouvertes.fr/inserm-00442929
Radiobiology and Dosimetry of Alpha-Particle Emitters for Targeted Radionuclide Therapy, MIRD Pamphlet No. J. Nucl. Med, vol.22, issue.51, pp.311-328, 2010. ,
Development of a large scale production of 67Cu from 68Zn at the high energy proton accelerator: Closing the 68Zn cycle, Development of a Large Scale Production of 67 Cu from 68 Zn at the High Energy Proton Accelerator: Closing the 68 Zn Cycle, pp.423-429, 2012. ,
DOI : 10.1016/j.apradiso.2011.10.007
Current Status and Perspectives in Alpha Radioimmunotherapy, Q. J. Nucl. Med. Mol. Imaging, vol.50, pp.322-329, 2006. ,
Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril, Biochemical and Biophysical Research Communications, vol.80, issue.4, pp.849-857, 1978. ,
DOI : 10.1016/0006-291X(78)91322-0
Evaluation of an anti-p185HER2 (scFv-CH2-CH3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-d-GEEEK, Nuclear Medicine and Biology, vol.36, issue.6, pp.671-680, 2009. ,
DOI : 10.1016/j.nucmedbio.2009.04.002
Bifunctional Chelates for Metal Nuclides, Q. J. Nucl. Med. Mol. Imaging, vol.52, pp.166-173, 2008. ,
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and90yttrium-DOTA-peptide-ChL6, The Prostate, vol.159, issue.1, pp.27-37, 2002. ,
DOI : 10.1016/S0022-5347(01)63990-9
High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody, Clinical Cancer Research, vol.11, issue.16, pp.5920-5927, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0211
Treatment of Metastatic Prostate Carcinoma with Radiolabeled Antibody CC49, J. Nucl. Med, vol.35, pp.1017-1022, 1994. ,
A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine, The Prostate, vol.55, issue.2, pp.150-157, 2000. ,
DOI : 10.1016/1078-1439(95)00004-2
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues, Urologic Oncology: Seminars and Original Investigations, vol.1, issue.1, pp.18-28, 1995. ,
DOI : 10.1016/1078-1439(95)00002-Y
Expression of the Prostate-Specific Membrane Antigen, Cancer Res, vol.54, pp.1807-1811, 1994. ,
Molecular Cloning of a Complementary DNA Encoding a Prostate-Specific Membrane Antigen, Cancer Res, vol.53, pp.227-230, 1993. ,
Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients, Anticancer Res, vol.7, pp.927-935, 1987. ,
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma, Cancer, vol.49, issue.11, pp.2256-2261, 1998. ,
DOI : 10.1016/S0090-4295(97)00175-1
Constitutive and Antibody-Induced Internalization of Prostate-Specific Membrane Antigen, Cancer Res, vol.58, pp.4055-4060, 1998. ,
Monoclonal Antibodies to the Extracellular Domain of Prostate-Specific Membrane Antigen Also React with Tumor Vascular Endothelium, Cancer Res, vol.57, pp.3629-3634, 1997. ,
Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer, Journal of Clinical Oncology, vol.23, issue.21, pp.4591-4601, 2005. ,
DOI : 10.1200/JCO.2005.05.160
,
Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer, Clin. Cancer Res. 2013, vol.19, pp.5182-5191 ,
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proc. Natl. Acad. Sci, pp.6841-6846, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-0420
A Universal Pretargeting System for Cancer Detection and Therapy Using Bispecific Antibody, Cancer Res, vol.63, pp.354-363, 2003. ,
Bispecific Antibody Pretargeting PET (immunoPET) with an 124 I-Labeled Hapten-Peptide, J. Nucl. Med, vol.47, pp.1678-1688, 2006. ,
A Novel Method of 18F Radiolabeling for PET, Journal of Nuclear Medicine, vol.50, issue.6, pp.991-998, 2009. ,
DOI : 10.2967/jnumed.108.060418
,
Pretargeted 177 Lu Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colonic Tumors in Mice, J. Nucl. Med, vol.51, pp.1780-1787, 2010. ,
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.9, issue.Suppl 1, pp.1593-1602, 2014. ,
DOI : 10.1089/cbr.2006.21.106
Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide, European Journal of Nuclear Medicine and Molecular Imaging, vol.14, issue.9, pp.2153-2164, 2011. ,
DOI : 10.1158/1078-0432.CCR-07-2031
Radiation Dosimetry, Toxicity and Tumor Regression in Patients with Lymphoma, Mausner, L.F.; et al. 67 Cu-2IT-BAT-Lym-1 Pharmacokinetics, pp.302-310, 1999. ,
Are Radiometal-Labeled Antibodies Better Than Iodine-131???Labeled Antibodies: Comparative Pharmacokinetics and Dosimetry of Copper-67???, Iodine-131???, and Yttrium-90???Labeled Lym-1 Antibody in Patients with Non-Hodgkin's Lymphoma, Clinical Lymphoma, vol.1, issue.2, pp.118-126, 2000. ,
DOI : 10.3816/CLM.2000.n.010
Comparison of Copper-67-and Iodine-125-Labeled Anti-CEA Monoclonal Antibody Biodistribution in Patients with Colorectal Tumors, J. Nucl. Med, vol.38, pp.847-853, 1997. ,
Separation of carrier-free47Sc from titanium targets, Journal of Radioanalytical and Nuclear Chemistry Articles, vol.13, issue.2, pp.335-345, 1992. ,
DOI : 10.1016/S0301-4770(08)60969-0
Promises of Cyclotron-Produced 44Sc as a Diagnostic Match for Trivalent ??--Emitters: In Vitro and In Vivo Study of a 44Sc-DOTA-Folate Conjugate, Journal of Nuclear Medicine, vol.54, issue.12, pp.2168-2174, 2013. ,
DOI : 10.2967/jnumed.113.123810
A Unique Matched Quadruplet of Terbium Radioisotopes for PET and SPECT and for ??- and ??--Radionuclide Therapy: An In Vivo Proof-of-Concept Study with a New Receptor-Targeted Folate Derivative, Journal of Nuclear Medicine, vol.53, issue.12, pp.1951-1959, 2012. ,
DOI : 10.2967/jnumed.112.107540
, , pp.1233-1239, 2002.
213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma, Journal of Nuclear Medicine, vol.54, issue.9, pp.1597-1604, 2013. ,
DOI : 10.2967/jnumed.112.111997
Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma, Cancer, vol.335, issue.S4, pp.1202-1209, 2002. ,
DOI : 10.1002/cncr.10286
Tumor Therapy with Targeted Atomic Nanogenerators, Science, vol.294, issue.5546, pp.1537-1540, 2001. ,
DOI : 10.1126/science.1064126
Pharmacokinetics, Dosimetry, and Toxicity of the Targetable Atomic Generator, 225 Ac-HuM195, in Nonhuman Primates, J. Nucl. Med, vol.45, pp.129-137, 2004. ,
, Dose Escalation and Dosimetry of First-in-Human ? Radioimmunotherapy with 212
, J. Nucl. Med, vol.2014, issue.55, pp.1636-1642
Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients, Cancer Biotherapy & Radiopharmaceuticals, vol.29, issue.1, pp.12-17 ,
DOI : 10.1089/cbr.2013.1531
Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody, Physics in Medicine and Biology, vol.56, issue.3, pp.721-733, 2011. ,
DOI : 10.1088/0031-9155/56/3/012
Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice, Current Radiopharmaceuticals, vol.6, issue.2, pp.106-116 ,
DOI : 10.2174/18744710113069990018
Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb, PLoS ONE, vol.49, issue.7, p.69613, 2013. ,
DOI : 10.1371/journal.pone.0069613.g007
Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity., Proc. Natl. Acad. Sci. USA 1989, pp.7149-7153 ,
DOI : 10.1073/pnas.86.18.7149
Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate, Nuclear Medicine and Biology, vol.26, issue.4, pp.405-411, 1999. ,
DOI : 10.1016/S0969-8051(98)00120-6
Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model, Blood, vol.121, issue.18, pp.3759-3767, 2013. ,
DOI : 10.1182/blood-2012-11-467035
URL : http://www.bloodjournal.org/content/bloodjournal/121/18/3759.full.pdf
, Z
, At: Treatment of Recurrent Brain Tumor Patients with 211 At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6, J. Nucl. Med, vol.49, pp.30-38, 2008.
, et al. Intraperitoneal Alpha-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of (211)At-MX35 F(ab'), p.2
, J. Nucl. Med, vol.50, pp.1153-1160, 2009.
A method for accurate modelling of the crystal response function at a crystal sub-level applied to PET reconstruction, Physics in Medicine and Biology, vol.56, issue.3, pp.793-809, 2011. ,
DOI : 10.1088/0031-9155/56/3/016
Recent advances and future advances in time-of-flight PET, Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, vol.580, issue.2, pp.919-924, 2007. ,
DOI : 10.1016/j.nima.2007.06.038
Recent developments in PET detector technology, Physics in Medicine and Biology, vol.53, issue.17, pp.287-317, 2008. ,
DOI : 10.1088/0031-9155/53/17/R01
Advances in Immuno???Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology, Journal of Clinical Oncology, vol.30, issue.31, pp.3884-3892, 2012. ,
DOI : 10.1200/JCO.2012.42.4887
Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications, Perk, L.R. Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications, pp.1379-1389, 2007. ,
DOI : 10.1634/theoncologist.12-12-1379
ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model, Journal of Nuclear Medicine, vol.51, issue.10, pp.1565-1572, 2010. ,
DOI : 10.2967/jnumed.110.075648
Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules, Journal of Nuclear Medicine, vol.51, issue.6, pp.892-897, 2010. ,
DOI : 10.2967/jnumed.109.073239
Pretargeted Immuno-Positron Emission Tomography Imaging of Carcinoembryonic Antigen-Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts, Molecular Cancer Therapeutics, vol.9, issue.4, pp.1019-1027, 2010. ,
DOI : 10.1158/1535-7163.MCT-09-0862
Performance of Immuno-Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients, Clinical Cancer Research, vol.12, issue.7, pp.2133-2140, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-2137
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30, European Journal of Nuclear Medicine and Molecular Imaging, vol.48, issue.Suppl 1, pp.1857-1867, 2008. ,
DOI : 10.1007/s00259-008-0774-5
Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial, Journal of Clinical Oncology, vol.31, issue.2, pp.31-187, 2013. ,
DOI : 10.1200/JCO.2011.41.2445
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial, The Lancet Oncology, vol.8, issue.4, pp.304-310, 2007. ,
DOI : 10.1016/S1470-2045(07)70044-X
Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250, Journal of Nuclear Medicine, vol.52, issue.4, pp.535-540, 2011. ,
DOI : 10.2967/jnumed.110.083295
Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer, J. Nucl. Med, vol.64, issue.54, pp.1869-1875, 2013. ,
DOI : 10.2967/jnumed.112.118612
URL : http://jnm.snmjournals.org/content/54/11/1869.full.pdf
Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma, European Journal of Nuclear Medicine and Molecular Imaging, vol.52, issue.5, pp.985-994, 2014. ,
DOI : 10.2967/jnumed.111.095596
Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers, Journal of Nuclear Medicine, vol.50, issue.2, pp.239-249, 2009. ,
DOI : 10.2967/jnumed.108.056655
PET of Hypoxia with 89Zr-Labeled cG250-F(ab')2 in Head and Neck Tumors, Journal of Nuclear Medicine, vol.51, issue.7, pp.1076-1083, 2010. ,
DOI : 10.2967/jnumed.109.073189
, Lub-de Hooge, M.N.; de Vries, E.G. Biodistribution of, p.89
Imaging of HER2-Positive Lesions in Patients with Metastatic Breast Cancer, Clin. Pharmacol. Ther, vol.87, pp.586-592, 2010. ,
Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET, Journal of Nuclear Medicine, vol.55, issue.1, pp.23-29, 2014. ,
DOI : 10.2967/jnumed.113.122630
URL : http://jnm.snmjournals.org/content/55/1/23.full.pdf
, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license